These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 29783691)

  • 1. Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance.
    Manni S; Carrino M; Semenzato G; Piazza F
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma.
    Ria R; Vacca A
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma.
    Yen CH; Hsiao HH
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30405034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment.
    Raimondi L; De Luca A; Morelli E; Giavaresi G; Tagliaferri P; Tassone P; Amodio N
    Biomed Res Int; 2016; 2016():6504593. PubMed ID: 26881223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New approaches to targeting the bone marrow microenvironment in multiple myeloma.
    Gooding S; Edwards CM
    Curr Opin Pharmacol; 2016 Jun; 28():43-9. PubMed ID: 27018230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
    Shay G; Hazlehurst L; Lynch CC
    J Mol Med (Berl); 2016 Jan; 94(1):21-35. PubMed ID: 26423531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Insights in Anti-Angiogenesis in Multiple Myeloma.
    Ribatti D; Vacca A
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30002349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma.
    Manier S; Kawano Y; Bianchi G; Roccaro AM; Ghobrial IM
    Curr Opin Hematol; 2016 Jul; 23(4):426-33. PubMed ID: 27101529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance.
    Shain KH; Landowski TH; Dalton WS
    Curr Opin Oncol; 2000 Nov; 12(6):557-63. PubMed ID: 11085455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noncoding RNAs in the crosstalk between multiple myeloma cells and bone marrow microenvironment.
    Tang W; Xu J; Xu C
    Cancer Lett; 2023 Mar; 556():216081. PubMed ID: 36739065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma.
    Wang J; Faict S; Maes K; De Bruyne E; Van Valckenborgh E; Schots R; Vanderkerken K; Menu E
    Oncotarget; 2016 Jun; 7(25):38927-38945. PubMed ID: 26950273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment.
    Shay G; Tauro M; Loiodice F; Tortorella P; Sullivan DM; Hazlehurst LA; Lynch CC
    Oncotarget; 2017 Jun; 8(26):41827-41840. PubMed ID: 28611279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNAs and exosomes: Small molecules with big actions in multiple myeloma pathogenesis.
    Pourhanifeh MH; Mahjoubin-Tehran M; Shafiee A; Hajighadimi S; Moradizarmehri S; Mirzaei H; Asemi Z
    IUBMB Life; 2020 Mar; 72(3):314-333. PubMed ID: 31828868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel therapeutic strategies for multiple myeloma.
    Mimura N; Hideshima T; Anderson KC
    Exp Hematol; 2015 Aug; 43(8):732-41. PubMed ID: 26118499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microenvironment drug resistance in multiple myeloma: emerging new players.
    Di Marzo L; Desantis V; Solimando AG; Ruggieri S; Annese T; Nico B; Fumarulo R; Vacca A; Frassanito MA
    Oncotarget; 2016 Sep; 7(37):60698-60711. PubMed ID: 27474171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The microenvironment and molecular biology of the multiple myeloma tumor.
    Lemaire M; Deleu S; De Bruyne E; Van Valckenborgh E; Menu E; Vanderkerken K
    Adv Cancer Res; 2011; 110():19-42. PubMed ID: 21704227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple Myeloma.
    Al-Odat OS; Guirguis DA; Schmalbach NK; Yao G; Budak-Alpdogan T; Jonnalagadda SC; Pandey MK
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Crosstalk between Chromatin Remodeling and Tumor Microenvironment in Multiple Myeloma.
    Chakraborty C; Mukherjee S
    Curr Oncol; 2022 Dec; 29(12):9535-9549. PubMed ID: 36547163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches.
    Kizaki M; Tabayashi T
    J Clin Exp Hematop; 2016; 56(1):20-7. PubMed ID: 27334854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.